Breaking News

Stelis BioSource Continues Facility Investment

Will install two 2,000L single-use bioreactor trains in its mammalian CGMP facility.

By: Contract Pharma

Contract Pharma Staff

Contract development and manufacturing organization (CDMO), Stelis BioSource, a division of Stelis Biopharma Pvt. Ltd., has started the next phase of its continued investment program after having already invested well over $100 million into its facilities in Bangalore, India.    The latest phase will see the company, which offers end-to-end development and manufacturing services for biologics and biosimilars companies, start work on installing two 2,000L single-use bioreactor trains in its mamma...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters